Hepatitis B in Nigeria 2025
The Silent Epidemic 8% of You Are Living With

Why Nigeria Has One of the World's Highest Hepatitis B Rates

Hepatitis B virus (HBV) infects the liver and can cause chronic infection leading to cirrhosis and liver cancer. Nigeria's burden — estimated at 8–11% carrier prevalence — reflects the predominant transmission route: mother-to-child at birth and early childhood horizontal transmission (through cuts, shared razors, or close household contact).

Unlike HIV (where transmission typically occurs in adulthood and the adult immune system mounts a partial response), HBV acquired in early childhood becomes chronic in 90% of cases — because the immature immune system cannot clear it. The result is millions of Nigerians carrying a liver-damaging virus they acquired before they could walk.

The Lifecycle of Hepatitis B — and When It Becomes Dangerous

After infection, HBV goes through distinct phases:

• Immune-tolerant phase: High viral replication, normal liver enzymes, minimal liver damage. Can last decades. Most carriers are in this phase and feel completely well.
• Immune-active phase: The immune system attacks infected liver cells — causing elevated liver enzymes and progressive inflammation. This is when antiviral treatment is most indicated.
• Inactive carrier phase: Low viral replication, normal liver enzymes. Liver damage from the immune-active phase may have occurred.
• Reactivation: Inactive carriers can reactivate — particularly during immunosuppression (chemotherapy, steroids, HIV) — causing sudden severe hepatitis.

The transition from carrier to liver cancer (hepatocellular carcinoma — HCC) typically takes 20–40 years of chronic inflammation. Nigeria has extremely high rates of HCC — the majority attributable to HBV. Annual ultrasound monitoring of the liver in HBV carriers is the intervention that detects HCC when it is still resectable.

Testing and Vaccination — the Two Interventions That Eliminate Risk

Testing

A full hepatitis B profile (HBsAg, anti-HBs, HBeAg, anti-HBe, anti-HBc) tells you whether you are: currently infected, immune from past infection, immune from vaccination, or susceptible (never infected and never vaccinated). This one blood panel determines your entire management pathway.

Vaccination

The hepatitis B vaccine is one of the most effective vaccines in existence — providing >95% protection against HBV infection. Three doses are required. For non-immune adults in Nigeria, vaccination is urgently recommended — particularly healthcare workers, household contacts of carriers, and anyone with a new sexual partner.

Antiviral treatment

Tenofovir and entecavir suppress HBV replication to undetectable levels, preventing progressive liver damage. Not all carriers need treatment — the decision is based on HBV DNA, ALT level, and liver biopsy/fibroscan results. Annual monitoring is required for all carriers, with treatment started when indicated criteria are met.

About the author: Dr. Adebayo Okonkwo is general practitioner, mascot healthcare at Mascot Healthcare, Akoka, Lagos. This article is reviewed annually and updated to reflect current guidelines and data.